

ABSTRACT

Accurate and robust quantification of insulin-like growth factor 1 (IGF-1) from serum using mass spectrometry (MS) is challenging due to its high complexity and dynamic range. Low cost, high throughput enrichment method for such low abundant proteins from the serum is required to enrich target proteins prior to MS analysis. We report a high-throughput sample preparation method using reverse phase micro-solid phase extraction enrichment on Microlab[®]NIMBUS[®] robotic liquid handling system from Hamilton Robotics and demonstrated over 71% recovery from serum for 96 samples in less than 30 minutes. IGF-1 levels in serum correlates well to other published methods that involve longer processing times.

INTRODUCTION

Insulin-like growth factor 1 (IGF-1) is a polypeptide hormone that plays an import role in childhood growth and continues to have anabolic effects in adults. Accurate and robust quantification of IGF-1 from serum using mass spectrometry (MS) is challenging due to its high complexity and dynamic range. Low cost, high throughput enrichment method for such low abundant proteins from the serum is required to enrich target proteins prior to MS analysis. Herein, we report a high-throughput sample preparation method using reverse phase micro-solid phase extraction enrichment on a robotic liquid handling system.

MATERIALS AND METHODS

Two peptides of IGF-1 were selected for multiple reaction monitoring and the transition conditions were optimized. 100 ng of IGF-1 was spiked in 80 μ g BSA and *E. coli* digest and isolated using automated pipetting system (Figure 1). Three different binding buffers were used: 10% acetonitrile (ACN), 2% acetic acid (Buffer A, pH 3), 10% ACN, 100 mM ammonium bicarbonate (Buffer B, pH 8), and 10% ACN, 100 mM ammonium bicarbonate, 1% ammonium hydroxide (Buffer C, pH 10). 5 mg divinylbenzene (DVB) loose resin in IMCStips[™] was activated with 100% acetonitrile three times and then equilibrated with binding buffer. Samples were add to 100 μ L binding buffer and enriched by pipetting sample 20 times. Non-specific binding proteins were removed by pipetting 150 μ L binding buffer three times twice and bound IGF-1 was eluted with 70% ACN, 100 mM ammonium bicarbonate buffer. Organic solvent was dried under nitrogen flow for 20 minutes and 10 mM dithiothreitol was added for denaturing at 65 $^{\circ}$ C for 30 min. Then 25 mM iodoacetamide was added for alkylation in dark for 30 minutes followed by 2 μ g trypsin addition for enzymatic digestion at 37 $^{\circ}$ C overnight.

To measure enriched IGF-1 amount, we used UPLC TSQ-Endura triple quadrupole mass spectrometry with optimized conditions. Briefly, digested peptides were separated on C18 column (ThermoFisher, Synchronis, 100 x 2.1 mm, 1.7 μ m) 5% - 50% acetonitrile, 0.1% formic acid gradient for 15 minutes and 769.7 m/z (T1) and 556.6 m/z (T2) precursor ions were selected for fragments of quantification (Figure 2). The area under the curve (AUC) of enriched samples were compared with the equal amount of exogenous IGF-1 protein standard.

- 100 ng of human recombinant IGF-1 was spiked in 100 μ g protein mixture and 20 μ g rat serum, respectively
- IMCS DVB tips on automatic pipetting system
- LC-MS/MS analysis to quantitate three IGF-1 peptides
- Thermo TSQ Vanquish UPLC
- Thermo TSQ Endura

- Mobile phase A: 0.1% formic acid in water
- Mobile phase B: 0.1% formic acid in acetonitrile
- LC gradient: 5% B - 50% B for 15min or 30 min
- Column: ThermoFisher, Synchronis C18, 100 x 2.1 mm, 1.7 μ m
- Column oven 40 $^{\circ}$ C

RESULTS

We established targeted LC-MS/MS analysis for the human IGF-1 and heavy isotope labeled IGF-1 (Table 1). We successfully demonstrated a linear calibration curve in a range from 1 ng to 16 ng IGF-1 with $R^2=0.999$ (Figure 3). Using DVB IMCStips with high-throughput robotic system, target protein was enriched within 30 minutes. We achieved 72% recovery of the IGF-1 T2 peptide from 100 μ g of protein mixture using pH 10 binding buffer (Figure 4). Additionally, we demonstrated the quantification of the human IGF-1 standard in rat serum with/without DVB IMCStips enrichment (Figure 5).




Figure 1. (a) IMCStips diagram (b) Nimbus96 automated liquid handler.

Table 1. Selected Reaction Monitoring (SRM) of IGF-1 peptides and Angiotensin II.

Name	Peptide Sequence	Precursor m/z	Product m/z	Collision	Charge State
IGF1-T1	GPETLCGAELVDALQFVCGDR	769.696	1180.54	19	3
IGF1-T1	GPETLCGAELVDALQFVCGDR	769.696	881.39	22	3
IGF1-T1	GPETLCGAELVDALQFVCGDR	769.696	507.19	22	3
IGF1-T1h	GPETLCGAELVDALQFVCGDR	773.032	1190.19	19	3
IGF1-T1h	GPETLCGAELVDALQFVCGDR	773.032	891.40	22	3
IGF1-T1h	GPETLCGAELVDALQFVCGDR	773.032	517.20	22	3
IGF1-T2	GFYFNKPTGYGSSSR	556.598	911.42	16	3
IGF1-T2	GFYFNKPTGYGSSSR	556.598	732.34	16	3
IGF1-T2	GFYFNKPTGYGSSSR	556.598	650.81	23	3
IGF1-T2h	GFYFNKPTGYGSSSR	562.606	921.43	16	3
IGF1-T2h	GFYFNKPTGYGSSSR	562.606	741.36	16	3
IGF1-T2h	GFYFNKPTGYGSSSR	562.606	659.82	23	3
Angiotensin II	DRVYIHPF	349.518	371.203	13	3
Angiotensin II	DRVYIHPF	349.518	513.282	13	3




Figure 2. Total Ion Chromatogram and SRM of IGF1 and Angiotensin II, (a) Total Ion chromatogram of the 5 ng IGF1 digest and SRM transition of T2 peptide, (b) Representative extracted ion chromatogram of the enriched IGF1 using DVB IMCStips.




Figure 3. Linear calibration curve of the IGF1 T2 peptide for 1, 2, 4, 8, and 16 ng amount.




Figure 4. Recovery of IGF-1 with DVB IMCStips, Area under the curve of the 100 ng IGF-1 standard in 100 μ g protein mixture was compared with three binding buffers.




Figure 5. Detection of human IGF-1 T2 peptide in rat serum. 100 ng human IGF-1 was spiked in 20 μ g rat serum and digested with trypsin. The area under the curves of the 2 ng IGF-1 standard in the rat serum and DVB IMCStips enriched IGF-1 T2 peptides with three different pH conditions are shown.

CONCLUSIONS

We successfully developed a dispersive pipette enrichment method to capture low abundant protein targets from high complex specimen for high-throughput sample preparation and analysis.

REFERENCES

1. Yan, J., Herzog, J., Tsang, K., Brennan, C., Bower, M., Garrett, W., Sartor, B., Aliprantis, A. and Charles, J. (2016) 'Gut microbiota induce IGF-1 and promote bone formation and growth', *Proceedings of the National Academy of Sciences of the United States of America.*, 113(47).
2. M'hamdi, H., Baizig, N., ELHadj, O., Attia, Z., Gritli, S., Gamoudi, A., May, E. and A, E. (2016) 'Usefulness of IGF-1 serum levels as diagnostic marker of nasopharyngeal carcinoma', *Immunobiology.*, 221(11), pp. 1304-8.
3. Mohan, S. and Baylink, D. (1995) 'Development of a simple valid method for the complete removal of insulin-like growth factor (IGF)-binding proteins from IGFs in human serum and other biological fluids: Comparison with acid-ethanol treatment and C18 Sep-Pak separation', *The Journal of clinical endocrinology and metabolism.*, 80(2), pp. 637-47.
4. Kay, R., Halsall, D., Annamalai, A., Kandasamy, N., Taylor, K., Fenwick, S., Webb, A., Wark, G., Pleasance, S. and Gurnell, M. (2012) 'A novel mass spectrometry-based method for determining insulin-like growth factor 1: Assessment in a cohort of subjects with newly diagnosed acromegaly', *Clinical endocrinology.*, 78(3), pp. 424-30.
5. Cox, H., Lopes, F., Woldemariam, G., Becker, J., Parkin, M., Thomas, A., Butch, A., Cowan, D., Thevis, M., Bowers, L. and Hoofnagle, A. (2013) 'Interlaboratory agreement of insulin-like growth factor 1 concentrations measured by mass spectrometry', *Clinical chemistry.*, 60(3), pp. 541-8.
6. Ketha, H. and Singh, R. (2015) 'Clinical assays for quantitation of insulin-like-growth-factor-1 (IGF1)', *Methods (San Diego, Calif.)*, 81, pp. 93-8.

¹Contact: Andrew Lee - lee@imcstips.com

²Contact: Michael Mouradian - michael.mouradian@hamiltoncompany.com

Artwork and layout created by Carmen Adamson.

© 2017 IMCS, Inc. All rights reserved.

IMCStips[®] is a trademark of Integrated Micro-Chromatography Systems, Inc. Microlab[®] NIMBUS[®] is a registered trademark of Hamilton Robotics (Reno, NV)